ReviewHealth science reports2026
Abdominal Obesity Phenotypes and Incidence of Type 2 DM, Cardiovascular Outcomes and All-Cause Mortality-A Systematic Review and Meta-Analysis.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Abdominal Obesity Phenotypes and Incidence of Type 2 DM, Cardiovascular Outcomes and All-Cause Mortality-A Systematic Review and Meta-Analysis.Health science reports · 2026Review
- Association of obesity-metabolic phenotypes with coronary artery disease prevalence: interaction and exploratory mediation analyses of high-sensitivity C-reactive protein.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The global rise in obesity, a major driver of metabolic diseases, has prompted scrutiny of distinct obesity phenotypes. While overall obesity is concerning, abdominal obesity demonstrates a stronger association with metabolic dysfunction, type 2 diabetes (DM2), and cardiovascular disease (CVD). This review examines the risk of DM2, CVD, and mortality in adults with a metabolically healthy abdominal obese phenotype. Methods: A systematic search of PubMed/MEDLINE, Web of Science, Cochrane Library, and ProQuest was conducted on April 7, 2025, to identify prospective cohort studies in adults. Eligible studies compared MHAO individuals to metabolically healthy, non-abdominally obese (MHNAO) controls, focusing on outcomes including incident T2DM, fatal and non-fatal CVD events, and all-cause mortality. Pooled estimates were calculated using random-effects meta-analysis, and heterogeneity was assessed using the Results: Six prospective cohort studies ( Conclusion: While metabolically unhealthy phenotypes are strongly associated with adverse health outcomes, individuals with MHAO appear to have risk profiles comparable to their metabolically healthy, non-abdominally obese counterparts. Nevertheless, abdominal adiposity and metabolic status remain critical determinants of long-term health, and the MHAO phenotype may not be entirely benign.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.